You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

58 search results for: guidelines

expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

3 min

Rhinology

Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

interactivity

Partnering With Patients: Scores That Matter in CRSwNP

5 min

Rhinology

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

interactivity

Eosinophilic Esophagitis (EoE) Pediatric Interactive Patient Case

8 min

Gastroenterology

Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.

expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

8 min

Rhinology

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.

expert video

How Can FeNO Measurement Improve Severe Asthma Management?

7 min

Pulmonology

Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.

interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

10 min

Dermatology

Gain insights with Prof. Lisa Beck: Explore the link between skin barrier dysfunction and type 2 inflammation in atopic dermatitis.

expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

10 min

Rhinology

Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.

expert video

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

21 min

Rhinology

Join Profs. Martin Wagenmann and Eugenio De Corso as they discuss type 2 inflammation in CRSwNP and explore real-world data on biologic efficacy.

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

24 min

Pulmonology

Join Drs. Len Bacharier and Sharon Dell as they highlight the natural course of pediatric asthma progression over time.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region